← board
CTRVP
Hepion Pharmaceuticals, Inc.distress 3/10 · well-funded / low risk$0.000%today0% from 52w high
Metabolic / Obesity 1
Lead: Nonalcoholic Steatohepatitis (NASH) · est. market ~$10B (approx, global)
Revenue
pre-revenue
Liquidity
$3M
Runway
1.6 yrs
Shares 1y
+151%
Price & events
+0.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+0.0%
1M
+0.0%
3M
+0.0%
6M
—
1Y
—
2Y
—
5Y
+0.0%
All
Overview
- Market Cap
- $37.85K
- Volume
- 0
- 52 Week Range
- $0.00 – $0.00
- Total Shares
- 29.12M
- Float Shares
- 20.37M
- Beta
- 1.63
Pipeline stages · 1 programs
Rencofilstat
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-05 | Phase 2 | Rencofilstat | Nonalcoholic Steatohepatitis (NASH), Fibrosis, Liver, NAFLD | 120 | unknown |
Catalyst news & presentations · 2
- 2026-03-03partnershipctRNA biomarker assay · In-licensed ctRNA biomarker assay from Cirna Diagnostics for early diagnosis of hepatocellular carcinoma; includes milestone payments and royalties.SEC 8-K
- 2024-12-10withdrawalMerger Agreement with Pharma Two B terminatedSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 29,119,317 · 0 offerings/1y · 0 PIPEs
- 2024-07-11S-1shelf_registration
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — Nonalcoholic Steatohepatitis (NASH)
- none identified
Recent news
- 2026-07-14Hepion Pharmaceuticals (HEPA) Proxy Filing Summary - Quartr
- 2026-07-13Hepion Pharmaceuticals (HEPA) Proxy Filing Summary - Quartr
- 2026-07-13Hepion Pharmaceuticals (HEPA) Proxy Filing Summary - Quartr
- 2026-07-13Hepion Pharmaceuticals (HEPA) Proxy filing Summary - Quartr
- 2026-07-13Hepion Pharmaceuticals (HEPA) Q4 2025 earnings summary - Quartr
- 2026-07-08Hepion Pharmaceuticals (HEPA) director Danina Fisher files initial Form 3 - Stock Titan
- 2026-07-07Hepion Pharmaceuticals keeps the focus on its pipeline - Ad-hoc-news.de
- 2026-06-26Hepion Pharmaceuticals updates CRV431 liver program, shares follow biotech peers - Ad-hoc-news.de
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.